Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 338 followers
Latest posts
Last updated about 2 hours ago
BMS CEO Boerner doesn’t ‘feel any compulsion to make deals’ despite lack of M&A this year
about 2 hours ago
BMS may have been absent from the dealmaking spree of some of...
Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat
about 4 hours ago
Investors awaiting Bristol Myers Squibb’s key Alzheimer’s psychosis readout for Cobenfy and...
GSK pens $110M biological datasets pact with AI biotech Relation
about 5 hours ago
GSK is boosting its AI chops with a new deal worth up...
Attovia, Braveheart and Vogenx seek more than $500M across trio of IPOs
about 5 hours ago
Attovia Therapeutics, Braveheart Bio and Vogenx have set target ranges for their...
Boston Scientific cuts guidance again after unveiling restructuring plan
about 5 hours ago
Boston Scientific is cutting its financial guidance for the second quarter in...
Takeda scraps another phase 2 celiac disease therapy, narrowing pipeline to one
about 5 hours ago
Takeda has dropped another celiac disease therapy from its phase 2 pipeline...
Labcorp posts higher Q2 earnings on strength of diagnostics, lab services; adjusts full-year guidance
about 6 hours ago
Labcorp continues to power along as it posts strong quarterly earnings led...
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
about 9 hours ago
Sanofi's new CEO Belén Garijo opened up for the first time about...
J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout
about 9 hours ago
Johnson & Johnson is cruising deeper into in vivo CAR-T waters, paying...
FDA adcomm shoots down Capricor's Duchenne cell therapy after meeting marked by statistical dispute
about 20 hours ago
A panel of experts today voted against Capricor’s cell therapy for Duchenne...
Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
about 23 hours ago
After keeping tight-lipped for nearly two years, Merck & Co. briefly dropped...
‘Low tech’ chemotherapy nanoparticles show promise for deadly brain tumor recurrence
about 24 hours ago
A standard chemotherapy drug loaded in nanoparticles has been able to penetrate...